See today's BioWorld
To read the full article sign up for free or sign in.

Abogen raises $300M in series C+ round for COVID-19 vaccine development

Dec. 1, 2021
By Doris Yu
Abogen Biosciences Co. Ltd. has raised $300 million in a series C+ round to support the development of its mRNA products, specifically to support the development of its COVID-19 mRNA vaccine and expand to the global market.
BioWorld Financings Coronavirus Vaccine Series C China